【摘要】 目的:研究依达拉奉治疗脑梗死时对丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)的影响及疗效。方法:入选200例患者,随机分为依达拉奉组105例、对照组95例,在治疗前、治疗后第4、7、11、15天采静脉血测定MDA、SOD、GSH-Px浓度,并进行治疗前、后ESS评定。结果:与治疗前相比,治疗后第11、15天按欧洲神经功能缺损评分量表(ESS)衡量明显增高,(P<0.01)。治疗后第4、7、11、15天,MDA较治疗前降低,(P<0.01);SOD、GSH-Px较治疗前升高,(P<0.01)。在第15天时,三者处于稳定状态。结论:依达拉奉降低MDA,升高SOD、GSH-Px,清除自由基,保护脑细胞,有助于降低脑梗死致残率。更多还原

【Abstract】 Objective: Edaravone,a free radical scavenger approved for treatment of acute cerebral infarction(ACI);the purpose of the present study was to evaluate its efficacy including investigating sequential changes in serum concentrations of malondialdehyde(MDA),superoxide dismutase(SOD),glutathione peroxides(GSH-Px) in patients with ACI.Method: Within an open trial design,200 subjects with ACI received either 60~30mg(105 subjects) of edaravone via intravenous drip or routine treatment(95 subjects).10 days of administration was followed by a two-week observation period and the efficacy was evaluated by European stroke scales(ESS).Results: ESS score of the 11th and 15th day after treatment was markedly raised than that before(p<0.01),the serum MDA level was decreased on the 4th 7th 11th 15th day after treatment(p<0.01),and the concentration of SOD,GSH-Px were raised respectively(p<0.01).Conclusion: Data from the present study suggest that edaravone is safe and may reduce the disablement rate of ACI by reducing MDA level and increasing the concentration of SOD and GSH-Px.更多还原